Dementia | I & C | Invest in Quality. Contribute to Society.


ProductStrengthPack Size
Donepezil Hydrochloride Tablets5mg100 tablets / box
Donepezil Hydrochloride Tablets10mg100 tablets / box
Galantamine Prolonged-Release Capsules8mg28 capsules / box
Galantamine Prolonged-Release Capsules16mg28 capsules / box
Galantamine Prolonged-Release Capsules24mg28 capsules / box
* The above product list shows our products which are approved by Hong Kong Department of Health only. It does not mean that all products are already placed in the market. For any product or business enquiries please contact us at or (852) 2891 0581 for further details.


Dementia refers to decline in cognition in one or more domains e.g. learning and memory, language, executive function and social cognition. The most common neurodegenerative conditions are Alzheimer’s disease which mainly affect the elderly. Currently, there is no cure or disease modifying therapy. All the treatments available are for symptomatic relief only.

Acetylcholinesterase inhibitors
Acetylcholinesterase inhibitors exert their therapeutic action by inhibiting the degradation of acetylcholine and increasing cholinergic transmission. Most adverse events are cholinergic in nature, e.g. nausea, vomiting and diarrhea, that are generally mild and transient. Donepezil, Rivastigmine and Galantamine are indicated for the treatment of mild to moderately severe dementia of the Alzheimer type.

NMDA receptor antagonist
Memantine exerts moderate benefits in patients with moderate to severe dementia of the Alzheimer type. It is recommended in patients with moderate dementia only if acetylcholinesterase inhibitors are contraindicated or not responding.